CEP
ACOR

Chicago Equity Partners’s Acorda Therapeutics ACOR Stock Holding History

Chicago Equity Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-665
Closed -$2.29M – 908
2018
Q2 		$2.29M Buy
+665
New +$2.04M 0.07% 361

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chicago Equity Partners's ACOR Position: Q3 2018 in Review

Chicago Equity Partners sold out of Acorda Therapeutics (ACOR) in Q3 2018, closing a stake of 665 shares — an estimated $2.29M sold.

Chicago Equity Partners first reported a position in ACOR in Q2 2018 and held it in 1 quarter. The position peaked at $2.29M in Q2 2018. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Chicago Equity Partners reported no remaining Acorda Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 665 Acorda Therapeutics shares in Q3 2018, an estimated $2.29M.
  • Chicago Equity Partners first reported a position in Acorda Therapeutics in Q2 2018 and held it in 1 quarter.
  • Chicago Equity Partners's Acorda Therapeutics position peaked at $2.29M in Q2 2018.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Chicago Equity Partners's 13F filing for Q3 2018, filed 1 Nov 2018.